Rates of both individual mutations and clinically relevant transmitted drug resistance were low among people newly diagnosed with HIV who were not previously on ART, according to a recent study.
“There is a lack of updated info on transmitted drug resistance in Europe — and in the rest of the world — and there is an interest in knowing how transmitted drug resistance (TDR) may impact the use of first-line regimens to treat HIV infection, specifically if the prevalence of TDR may justify a need to wait for a resistance test before first-line treatment,” Federico García, PharmD, PhD, vice president of the Spanish Society of Infectious Diseases and Clinical Microbiology, told Healio.
García and colleagues used data from MeditRes HIV — a consortium that includes ART-naive people with HIV who have been newly diagnosed in France, Greece, Italy, Portugal, and Spain between 2018 and 2021. According to the study, the researchers assessed reverse transcriptase and integrase (INSTI) sequences provided by participating centers to evaluate the prevalence of surveillance drug resistance mutations (SDRMs) and clinically relevant resistance (CRR).
